Contrarian watchlist stock entries

Which stocks just entered the contrarian watchlist?

{"response_type": "market_analysis", "acknowledgement": "Here's a list of stocks that are currently on the contrarian watchlist.", "answer": "**The stocks most recently entering the contrarian watchlist** are characterized by very low Z-scores, indicating they may be in contrarian territory based on valuation or sentiment metrics:\n\n- **PALANTIR TECHNOLOGIES INC (PLTR)** \u2014 Technology, Mega cap\n- **COPART INC (CPRT)** \u2014 Industrials, Large cap\n- **FRANCO NEVADA CORP (FNV)** \u2014 Basic Materials, Large cap\n- **UNITED THERAPEUTICS CORP (UTHR)** \u2014 Healthcare, Large cap\n- **ENLIVEX LTD (ENLV)** \u2014 Healthcare, Micro cap\n- **REDDIT INC (RDDT)** \u2014 Communication Services, Large cap\n- **MUELLER INDUSTRIES INC (MLI)** \u2014 Industrials, Large cap\n\nThese stocks have plunged into levels that typically suggest investor contrarian sentiment, possibly due to recent price drops, negative news, or sentiment extremes that may present opportunistic entry points. It\u2019s worth investigating whether fundamentals support a turnaround or if these are signs of deeper issues.\n\nWould you like to analyze a specific stock in detail, compare these to their peers, or explore sector implications?", "interpretation": "The low Z-scores indicate these stocks are seen as outliers that might be undervalued or ignored by majority sentiment\u2014classic contrarian signals. Risks include fundamental deterioration or sentiment overshoot; opportunities could arise if earnings or sentiment recover. It\u2019s prudent to examine each company\u2019s financial health and catalysts before acting.", "hypothesis": {"text": "These stocks entered contrarian zones due to recent price drops and sentiment extremes, suggesting potential undervaluation or sentiment panic that could reverse if fundamentals improve.", "confidence": "Moderate"}, "insights": ["Several stocks with very low Z-scores have large market caps, indicating potential contrarian opportunities in sizable names."], "suggested_questions": ["Analyze PLTR's recent earnings and outlook", "Compare CPRT to industry peers in valuations", "Check sector view for Healthcare stocks", "View ENLV page for more analysis"], "charts": [{"type": "bar", "title": "Top 10 Stocks Entering Contrarian Watchlist (Z-Score)", "data": [{"label": "PLTR", "value": 9.0}, {"label": "CPRT", "value": 9.0}, {"label": "FNV", "value": 9.0}, {"label": "UTHR", "value": 9.0}, {"label": "ENLV", "value": 9.0}, {"label": "RDDT", "value": 9.0}, {"label": "MLI", "value": 9.0}]}], "actions": [], "supporting_data": [{"label": "Rank: PLTR", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: CPRT", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: FNV", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: UTHR", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: ENLV", "value": "zscore=9.0", "source": "metrics"}], "risk_watch": "Visit the ticker pages (CPRT, ENLV, FNV) for full credit ratings, financial scores, and fundamental analysis.", "structured_data": null}

Check sector view for Healthcare stocks

{"response_type": "market_analysis", "acknowledgement": "Here's the week-long sector performance view for Healthcare stocks.", "answer": "**Healthcare sector (XLV)** increased by +1.02% over the latest session, reflecting a modest gain amid mixed market sentiment. Compared to other sectors:\n\n- **Technology (XLK)** up +1.09%\n- **Financials (XLF)** up +0.97%\n- **Utilities (XLU)** up +1.61%\n- **Consumer Staples (XLP)** up +1.14%\n- **Industrials (XLI)** up +0.72%\n- **Real Estate (XLRE)** up +0.64%\n- **Materials (XLB)** down -0.61%\n- **Consumer Discretionary (XLY)** down -1.38%\n- **Energy (XLE)** up +7.67%\n- **Communication Services (XLC)** up +1.53%\n\nThe Healthcare sector's performance aligns with broader defensive and growth sectors, showing resilience and a slight positive trend in the latest session.\n\nThis consistent performance suggests stability in healthcare, which could be driven by ongoing medical innovations or stable demand dynamics. However, sector-specific catalysts such as policy changes or pharmaceutical news could alter this trend.\n\nWould you like a deeper analysis on leading healthcare stocks or sector catalysts?", "interpretation": "The Healthcare sector's modest gain in the latest session reflects ongoing investor interest in defensive growth areas amid mixed market sentiment. It remains a relatively stable sector compared to more volatile or cyclical sectors, making it a potential defensive hold. Monitoring policy developments or breakthroughs in healthcare innovation could offer future catalysts.", "hypothesis": {"text": "Healthcare's steady performance indicates investor confidence in stability and growth prospects in the sector, possibly reinforced by macroeconomic resilience.", "confidence": "Moderate"}, "insights": ["Healthcare's weekly return of +1.02% is consistent with its defensive profile amid market fluctuations."], "suggested_questions": ["Check top Healthcare stocks for growth", "Analyze recent drug approvals in Healthcare sector", "Review earnings reports for XLV components"], "charts": [], "actions": [], "supporting_data": [{"label": "S&P 500", "value": "+0.36%", "source": "market_summary"}, {"label": "Dow Jones", "value": "-0.56%", "source": "market_summary"}, {"label": "Nasdaq", "value": "+0.14%", "source": "market_summary"}, {"label": "Russell 2000", "value": "+1.12%", "source": "market_summary"}, {"label": "VIX", "value": "-4.36%", "source": "market_summary"}], "risk_watch": "", "structured_data": {"template": "market_snapshot", "index_moves": [{"name": "S&P 500", "symbol": "^GSPC", "price": 7785.76, "change": 28.12, "change_pct": 0.36}, {"name": "Dow Jones", "symbol": "^DJI", "price": 53732.41, "change": -304.52, "change_pct": -0.56}, {"name": "Nasdaq", "symbol": "^IXIC", "price": 26729.16, "change": 38.54, "change_pct": 0.14}, {"name": "Russell 2000", "symbol": "^RUT", "price": 3068.42, "change": 33.93, "change_pct": 1.12}, {"name": "VIX", "symbol": "^VIX", "price": 14.25, "change": -0.65, "change_pct": -4.36}], "as_of_date": "2026-08-14", "sector_moves": [{"name": "Energy", "symbol": "XLE", "change_pct": 7.67}, {"name": "Utilities", "symbol": "XLU", "change_pct": 1.61}, {"name": "Communication Services", "symbol": "XLC", "change_pct": 1.53}, {"name": "Consumer Staples", "symbol": "XLP", "change_pct": 1.14}, {"name": "Technology", "symbol": "XLK", "change_pct": 1.09}, {"name": "Healthcare", "symbol": "XLV", "change_pct": 1.02}, {"name": "Financials", "symbol": "XLF", "change_pct": 0.97}, {"name": "Industrials", "symbol": "XLI", "change_pct": 0.72}, {"name": "Real Estate", "symbol": "XLRE", "change_pct": 0.64}, {"name": "Materials", "symbol": "XLB", "change_pct": -0.61}, {"name": "Consumer Discretionary", "symbol": "XLY", "change_pct": -1.38}], "style_size": [{"name": "Large Growth", "symbol": "VUG", "price": 89.34, "change": -0.39, "change_pct": -0.43, "volume": 5144600}, {"name": "Large Value", "symbol": "VTV", "price": 227.51, "change": 0.46, "change_pct": 0.2, "volume": 2027800}, {"name": "Mid Growth", "symbol": "VOT", "price": 314.02, "change": 0.58, "change_pct": 0.19, "volume": 142800}, {"name": "Mid Value", "symbol": "VOE", "price": 211.01, "change": 0.7, "change_pct": 0.33, "volume": 211000}, {"name": "Small Growth", "symbol": "VBK", "price": 365.89, "change": 0.54, "change_pct": 0.15, "volume": 177300}, {"name": "Small Value", "symbol": "VBR", "price": 251.66, "change": 0.66, "change_pct": 0.26, "volume": 187900}]}}

Check top Healthcare stocks for growth

{"response_type": "market_analysis", "acknowledgement": "Here's a list of the top Healthcare stocks with strong growth potential.", "answer": "**Leading Healthcare stocks by 3-year earnings CAGR:**\n\n- **TRANSMEDICS GROUP INC (TMDX)** \u2014 Mid cap, CAGR: 3.59%\n- **VERICEL CORP (VCEL)** \u2014 Mid cap, CAGR: 2.61%\n- **INFUSYSTEM HOLDINGS INC (INFU)** \u2014 Small cap, CAGR: 2.42%\n- **BRAINSWAY LTD (BWAY)** \u2014 Small cap, CAGR: 1.88%\n- **INSPIRE MEDICAL SYSTEMS INC (INSP)** \u2014 Mid cap, CAGR: 1.83%\n- **INCYTE CORP (INCY)** \u2014 Large cap, CAGR: 1.79%\n\nThese stocks demonstrate notable momentum in improving earnings over the past three years, potentially indicating growth trajectories within the sector.\n\nIt's advisable to further analyze their recent earnings reports, product pipelines, and strategic outlooks to confirm whether these growth trends can be sustained or amplified.\n\nWould you like a deep dive into any of these stocks' fundamentals or upcoming catalysts?", "interpretation": "The top performers suggest a mix of mid-cap and small-cap healthcare companies showing resilient earnings growth, possibly driven by innovative treatments, expanding market share, or favorable market conditions. Risks include sector-specific headwinds or valuation concerns, so due diligence is critical.", "hypothesis": {"text": "These stocks' moderate 3-year earnings CAGR reflects increasing demand or successful product launches, which could continue if macro and sector dynamics favor innovation and expansion.", "confidence": "Moderate"}, "insights": ["Most of the top growth stocks are mid or small cap, indicating room for expansion."], "suggested_questions": ["Check recent earnings reports for TMDX", "Compare VCEL's growth prospects with industry peers", "Search latest news on INFU's product pipeline"], "charts": [{"type": "bar", "title": "Top Healthcare Stocks by 3Y Earnings CAGR", "data": [{"label": "TMDX", "value": 3.59}, {"label": "VCEL", "value": 2.61}, {"label": "INFU", "value": 2.42}, {"label": "BWAY", "value": 1.88}, {"label": "INSP", "value": 1.83}, {"label": "INCY", "value": 1.79}]}], "actions": [], "supporting_data": [{"label": "Rank: TMDX", "value": "eps_3y_CAGR=3.586792613421551", "source": "metrics"}, {"label": "Rank: VCEL", "value": "eps_3y_CAGR=2.6088260801386944", "source": "metrics"}, {"label": "Rank: INFU", "value": "eps_3y_CAGR=2.4199518933533937", "source": "metrics"}, {"label": "Rank: BWAY", "value": "eps_3y_CAGR=1.8844991406148168", "source": "metrics"}, {"label": "Rank: INSP", "value": "eps_3y_CAGR=1.8314481885281864", "source": "metrics"}], "risk_watch": "", "structured_data": null}

Check recent earnings reports for TMDX

{"response_type": "market_analysis", "acknowledgement": "Here's a summary of TMDX's recent earnings and guidance updates.", "answer": "**Recent earnings highlights for TransMedics Group (TMDX):**\n\n- **Q2 2026 Earnings:** Reported EPS of $0.44, missing the estimate of $0.47 by -7.44%.\n- **Q2 Revenue:** $189.95M, surpassing the estimate of $183.64M.\n- **Q2 EPS surprise:** Negative at -7.44%, but revenue beat estimates.\n- **Previous quarter (Q1 2026):** EPS was $0.30, and revenue was approximately $150M.\n- **Guidance:** Raised FY2026 sales outlook from $727M-$757M to $737M-$757M, slightly above estimates.\n\nThe latest quarterly EPS missed forecasts, impacting share prices, but revenue growth remains positive. Management continues to emphasize growth over near-term operating leverage, and the company maintains an optimistic annual sales outlook.\n\nFor deeper insights, the upcoming earnings scheduled for August 4, 2026, will be key to watch for signs of earnings improvement or further guidance updates.", "interpretation": "Despite the EPS miss in the latest quarter, the revenue beat demonstrates ongoing top-line growth, supporting the case for future potential. The positive sales outlook and strategic focus on growth suggest investor confidence in long-term prospects. Risks include margin pressure from growth investments and competitive dynamics.", "hypothesis": {"text": "The EPS miss likely reflects transitional costs or investments, but revenue momentum indicates underlying demand growth that could rebound in upcoming quarters.", "confidence": "Moderate"}, "insights": ["Revenue growth remains strong despite short-term EPS variances, highlighting scale potential."], "suggested_questions": ["Check upcoming earnings for TMDX on Aug 29", "Review analyst revisions for TMDX guidance", "Search latest news on TMDX product launches"], "charts": [{"type": "bar", "title": "TMDX Quarterly Earnings & Revenue (2026 Q2)", "data": [{"label": "EPS Actual", "value": 0.44}, {"label": "EPS Estimate", "value": 0.47}, {"label": "Revenue ($M)", "value": 189.95}, {"label": "Revenue Estimate ($M)", "value": 183.64}]}], "actions": [], "supporting_data": [], "risk_watch": "", "structured_data": null}

Review analyst revisions for TMDX guidance

{"response_type": "market_analysis", "acknowledgement": "Here's the latest on analyst ratings and guidance revisions for TMDX.", "answer": "**Recent analyst guidance and rating updates for TMDX:**\n\n- The current mean price target is $97.3, with a high of $125 and a low of $65.\n- Recommendations from analysts remain mostly neutral to overweight:\n - 2 strong buys, 6 buys, 4 holds (latest in August 2026).\n- Notable recent upgrades include:\n - Piper Sandler maintained an Overweight rating on August 5, 2026.\n - TD Cowen and Canaccord Genuity reiterated Buy ratings in late June.\n- Recent downgrades or neutral ratings were also observed, notably from UBS and Stifel.\n\nThe consensus target suggests limited upside from current levels, but ratings are generally supportive of continued growth. The mixed guidance points to cautious optimism among analysts, with some expecting solid performance ahead.\n\nIt\u2019s advisable to revisit upcoming earnings and guidance calls for real-time updates on future outlooks.", "interpretation": "Analysts maintain a cautiously optimistic outlook for TMDX, reflected in mostly buy and overweight ratings. The guidance revisions and target prices imply room for upside, but also some caution given the mixed ratings. Keep an eye on upcoming quarterly results to assess if long-term growth remains supported.", "hypothesis": {"text": "The upgrade activity suggests analyst confidence is improving, possibly due to recent revenue or pipeline news, while some hold ratings reflect ongoing margin or execution concerns.", "confidence": "Moderate"}, "insights": ["Most analysts are still on buy/overweight ratings, supporting a positive outlook."], "suggested_questions": ["Check upcoming earnings for TMDX on Aug 29", "Review recent product pipeline news for TMDX", "Search latest analyst reports for TMDX"], "charts": [{"type": "bar", "title": "Recent Analyst Ratings for TMDX", "data": [{"label": "Strong Buy", "value": 2.0}, {"label": "Buy", "value": 6.0}, {"label": "Hold", "value": 4.0}, {"label": "Sell", "value": 0.0}, {"label": "Strong Sell", "value": 0.0}]}], "actions": [], "supporting_data": [], "risk_watch": "", "structured_data": {"template": "stock_analysis", "stocks": [{"ticker": "TMDX", "analyst": {"mean_target": 97.3, "high": 125.0, "low": 65.0, "buy": 8, "hold": 4, "sell": 0}}]}}

Review recent product pipeline news for TMDX

{"response_type": "market_analysis", "acknowledgement": "Here's the latest news about TMDX's product pipeline and strategic updates.", "answer": "**Recent product pipeline and strategic news for TMDX:**\n\n- According to the recent earnings call transcript from August 2026, management emphasized that TMDX is focusing on growth over near-term operating leverage. They highlighted a quarterly revenue figure, but specific figures were not detailed in the tool data.\n- In May 2026, TMDX reported mixed results for Q1, with solid top-line growth but profitability pressures, though the company remains committed to expanding its product offerings.\n- Recent news also mentions TMDX completing a PAD aviation investment to expand its presence in Europe, signaling ongoing international growth initiatives.\n- Analyst commentary suggests a bullish outlook with some analysts seeing a potential upside, driven by pipeline innovations and market expansion. The average price target is approximately $97.3, with a high of $125 and a low of $65, indicating some analyst optimism.\n\nWhile specific new product launches weren't detailed in these articles, strategic investments and revenue growth underscore TMDX's ongoing pipeline development and expansion plans across markets.", "interpretation": "The updates suggest TMDX is actively investing in growth initiatives and international expansion, which could serve as catalysts for future product launches. However, profitability pressures remain a near-term concern. Investors should watch upcoming earnings calls and analyst updates for details on pipeline progress and market acceptance.", "hypothesis": {"text": "TMDX's focus on growth and international expansion indicates potential upcoming product launches that could drive revenue upside, supported by analyst optimism.", "confidence": "Moderate"}, "insights": ["International expansion efforts, such as new investments in Europe, are strategic growth signals."], "suggested_questions": ["Check upcoming product launch events for TMDX", "Review recent patent filings or FDA approvals for TMDX", "Search analyst reports on TMDX pipeline prospects"], "charts": [], "actions": [], "supporting_data": [], "risk_watch": "", "structured_data": null}